Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER3 Solid Tumors - Benzinga
HILSDelisted Stock | USD 0.39 0.01 2.50% |
Slightly above 62% of Hillstream Biopharma's investor base is looking to short. The analysis of current outlook of investing in Hillstream Biopharma suggests that many traders are alarmed regarding Hillstream Biopharma's prospects. Hillstream Biopharma's investing sentiment can be driven by a variety of factors including economic data, Hillstream Biopharma's earnings reports, geopolitical events, and overall market trends.
Hillstream |
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER3 Solid Tumors Benzinga
Read at news.google.com
Hillstream Biopharma Fundamental Analysis
We analyze Hillstream Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hillstream Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hillstream Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Hillstream Biopharma is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Hillstream Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hillstream Biopharma stock to make a market-neutral strategy. Peer analysis of Hillstream Biopharma could also be used in its relative valuation, which is a method of valuing Hillstream Biopharma by comparing valuation metrics with similar companies.
Peers
Hillstream Biopharma Related Equities
CDIO | Cardio Diagnostics | 8.00 | ||||
IMMX | Immix Biopharma | 6.55 | ||||
UNCY | Unicycive Therapeutics | 3.92 | ||||
VRAX | Virax Biolabs | 3.61 | ||||
KPRX | Kiora Pharmaceuticals | 1.81 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
PALI | Palisade Bio | 0.41 | ||||
ZVSA | ZyVersa Therapeutics | 0.88 | ||||
QNRX | Quoin Pharmaceuticals | 4.84 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Hillstream Stock
If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |